Dan O'Day (AP Images)

Gilead CEO Dan O'­Day's $21B M&A deal to buy Im­munomedics gets some harsh re­views

Af­ter a wild, 4-year roller coast­er ride, Im­munoMedics $IM­MU is get­ting its fairy-tale end­ing af­ter all.

Sun­day evening Gilead $GILD put the week­end ru­mors to rest and an­nounced its agree­ment to buy out the com­pa­ny for $21 bil­lion, which gives the big biotech Trodelvy, new­ly ap­proved for metasta­t­ic triple neg­a­tive breast can­cer. That’s big mon­ey for a sin­gle-drug deal. Four years ago Im­munomedics’ stock sold for about $2 a share. It closed Fri­day at $42.25, and Gilead is pay­ing $88.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.